Assertio Therapeutics Announces Strong Second-Quarter 2019 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/25/2026
- Wall St edges up on AI enthusiasm, Mideast negotiation hopes
- Stock action shows confidence in central banks: BofA’s Hartnett
- Oil prices ease as US-Iran truce hopes counter Saudi supply risk
- Why stocks held up despite rising yields and $100 oil? These 2 words explain it
- Barclays asks if equity markets are nearing the boiling point
- Akamai signs $11.6B deal with Anthropic, up to $20B potential
- Bloom Energy falls as Oracle invokes force majeure on AI project
- Oracle triggers force majeure on massive 'Project Jupiter' data center
- Oracle Sends Force Majeure Notice Over New Mexico Data Center - Bloomberg
- S&P 500 ends marginally lower as investors focus on US-Iran war
Assertio Therapeutics (ASRT) Tops Q2 EPS by 1c
August 7, 2019 5:08 PM EDTAssertio Therapeutics (NASDAQ: ASRT) reported Q2 EPS of $0.25, $0.01 better than the analyst estimate of $0.24. Revenue for the quarter came in at $59.3 million versus the consensus estimate of $59.05 million.
For earnings history and earnings-related data on Assertio Therapeutics (ASRT) click here.
... More